Show simple item record

dc.contributor.authorHislop, J
dc.contributor.authorQuayyum, Z
dc.contributor.authorElders, A
dc.contributor.authorFraser, C
dc.contributor.authorJenkinson, D
dc.contributor.authorMowatt, G
dc.contributor.authorSharma, P
dc.contributor.authorVale, L
dc.contributor.authorPetty, R
dc.date.accessioned2011-09-13T14:05:05Z
dc.date.available2011-09-13T14:05:05Z
dc.date.issued2011
dc.identifier6635190
dc.identifier8a015860-943a-4185-9600-b38868afb5bd
dc.identifier21689502
dc.identifier79960807465
dc.identifier.citationHislop , J , Quayyum , Z , Elders , A , Fraser , C , Jenkinson , D , Mowatt , G , Sharma , P , Vale , L & Petty , R 2011 , ' Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day : a systematic review and economic evaluation ' , Health Technology Assessment , vol. 15 , no. 25 , pp. 1-178 . https://doi.org/10.3310/hta15250en
dc.identifier.issn2046-4924
dc.identifier.urihttp://hdl.handle.net/2164/2123
dc.format.extent178
dc.format.extent1615273
dc.language.isoeng
dc.relation.ispartofHealth Technology Assessmenten
dc.subjectR Medicineen
dc.subjectChief Scientist Office (CSO)en
dc.subjectCSO--HERU2en
dc.subjectCSO--HSRU1en
dc.subject.lccRen
dc.titleClinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day : a systematic review and economic evaluationen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.identifier.doi10.3310/hta15250


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record